Compare DexCom, Inc. (DXCM) vs Redwire Corporation (RDW) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Redwire Corporation (RDW) is trading at $8.505, down 12.68% in the last 24 hours amid a broader bearish technical signal. The company is in a high-growth but high-burn phase, with revenue of $335.38M in 2025 but significant net losses of -$226.55M. Recent news includes new defense contracts, but investor sentiment is mixed due to concerns over dilution from a planned $500M stock offering and persistent negative earnings. Analyst consensus remains bullish with an $19.00 price target, though the stock faces strong technical resistance near $10.

The outlook hinges on Redwire's ability to convert its growing backlog and contract wins into sustainable profitability. The significant cash burn and reliance on financing present a key risk. The substantial gap between the current price and the average analyst target suggests a high-risk, high-potential opportunity for investors who believe in the long-term space and defense infrastructure thesis.